Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio P Silva

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 6, 2002
Neuropeptide Y and its receptors as potential therapeutic drug targetsAntonio P Silva, Claudia Cavadas, Eric Grouzmann
European Journal of Endocrinology|June 9, 2005
Regulation of ghrelin secretion by somatostatin analogs in ratsAntonio P Silva, Kerstin Bethmann, Friedrich Raulf, et al.
Regulatory Peptides|November 6, 2003
NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVECAntonio P Silva, Claudia Cavadas, Bénédicte Baïsse-Agushi, et al.
Chimia|December 2, 2014
SOM230: a new therapeutic modality for Cushing's diseaseIan Lewis, Herbert A Schmid, Rainer Kneuer, et al.
Biology of the Cell|April 27, 2005
Neuropeptide Y expression, localization and cellular transducing effects in HUVECAntonio P Silva, Jocelyne E Kaufmann, Cécile Vivancos, et al.
Molecular Endocrinology (Baltimore, Md.)|October 15, 2005
SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?Weifeng Ruan, Fabian Fahlbusch, David R Clemmons, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Cancer Chemotherapy and Pharmacology|June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancerJordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 6, 2002
Neuropeptide Y and its receptors as potential therapeutic drug targetsAntonio P Silva, Claudia Cavadas, Eric Grouzmann
European Journal of Endocrinology|June 9, 2005
Regulation of ghrelin secretion by somatostatin analogs in ratsAntonio P Silva, Kerstin Bethmann, Friedrich Raulf, et al.
Regulatory Peptides|November 6, 2003
NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVECAntonio P Silva, Claudia Cavadas, Bénédicte Baïsse-Agushi, et al.
Chimia|December 2, 2014
SOM230: a new therapeutic modality for Cushing's diseaseIan Lewis, Herbert A Schmid, Rainer Kneuer, et al.
Biology of the Cell|April 27, 2005
Neuropeptide Y expression, localization and cellular transducing effects in HUVECAntonio P Silva, Jocelyne E Kaufmann, Cécile Vivancos, et al.
Molecular Endocrinology (Baltimore, Md.)|October 15, 2005
SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?Weifeng Ruan, Fabian Fahlbusch, David R Clemmons, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Cancer Chemotherapy and Pharmacology|June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancerJordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Pageof 1